Compare Howmet Aerospace Inc (HWM) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Howmet Aerospace (HWM) trades at $216.84, down 1.8% with bearish technical signals despite strong fundamentals. The company has consistently beaten earnings estimates in recent quarters with Q2 2026 EPS of $1.33 exceeding expectations. Revenue growth continues with 2026 projections showing $9.1B revenue and 20.52% net margin. Analyst consensus remains strongly bullish with 84% buy ratings and $328.10 price target representing 51% upside potential.

The stock presents compelling growth potential driven by aerospace demand and defense modernization trends, though technical weakness and valuation concerns at 46.7x P/E warrant caution. Strong cash flow generation supports shareholder returns including dividends and buybacks, while supply chain risks and competitive pressures remain key watchpoints for investors.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.